282
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Bortezomib in multiple myeloma

, &
Pages 639-654 | Published online: 18 May 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Serena Tschan, Benjamin Mordmüller & Jürgen FJ Kun. (2011) Threonine peptidases as drug targets against malaria. Expert Opinion on Therapeutic Targets 15:4, pages 365-378.
Read now

Articles from other publishers (18)

Katrin Sak. (2022) Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?. Current Cancer Drug Targets 22:9, pages 741-748.
Crossref
Crystal Loke, Peter Mollee, Ian McPherson, Euan Walpole, Mimi Yue, Howard Mutsando, Phillip Wong, Helen Weston, Ross Tomlinson & Samantha Hollingworth. (2020) Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal 50:9, pages 1059-1066.
Crossref
Lloyd D. Fricker. (2020) Proteasome Inhibitor Drugs. Annual Review of Pharmacology and Toxicology 60:1, pages 457-476.
Crossref
Jiang-Hua Ding, Li-Ya Yuan & Guo-An Chen. (2017) Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Oncology Letters 13:2, pages 647-654.
Crossref
Yali Li, Jun Li, Wenzhuo Zhuang, Qian Wang, Xueping Ge, Xiaohui Zhang, Ping Chen, Jinxiang Fu & Bingzong Li. (2014) Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro. Leukemia Research 38:8, pages 970-976.
Crossref
CHUANYING GENG, NIAN LIU, GUANGZHONG YANG, AIJUN LIU, YUN LENG, HUIJUAN WANG, LIHONG LI, YIN WU, YANCHEN LI & WENMING CHEN. (2013) Retrospective analysis of 264 multiple myeloma patients. Oncology Letters 5:2, pages 707-713.
Crossref
Julia S. Gelman, Juan Sironi, Iryna Berezniuk, Sayani Dasgupta, Leandro M. Castro, Fabio C. Gozzo, Emer S. Ferro & Lloyd D. Fricker. (2013) Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib. PLoS ONE 8:1, pages e53263.
Crossref
S. Legriel & E. Azoulay. (2012) Complications neurologiques des traitements anticancéreuxCancer treatment-related neurological toxicity. Réanimation 21:5, pages 613-624.
Crossref
Giovanni Marzaro, Valentina Gandin, Christine Marzano, Adriano Guiotto & Adriana Chilin. (2011) Psoralenquinones as a Novel Class of Proteasome Inhibitors: Design, Synthesis and Biological Evaluation. ChemMedChem 6:6, pages 996-1000.
Crossref
Hui-han Wang, Ying-chun Li, Ai-jun Liao, Bei-bei Fu, Wei Yang, Zhuo-gang Liu & Xiao-bin Wang. (2011) Reversion of multidrug-resistance by proteasome inhibitor bortezomib in K562/DNR cell line. Chinese Journal of Cancer Research 23:1, pages 69-73.
Crossref
Ashenafi Y Tilahun, Jayne E Theuer, Robin Patel, Chella S David & Govindarajan Rajagopalan. (2010) Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation. Molecular Therapy 18:6, pages 1143-1154.
Crossref
Evangelos Terpos. (2010) Bortezomib down-regulates the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease. Leukemia Research 34:6, pages 700-701.
Crossref
Melissa L. McIntosh, Cameron M. Moore & Timothy B. Clark. (2010) Copper-Catalyzed Diboration of Ketones: Facile Synthesis of Tertiary α-Hydroxyboronate Esters. Organic Letters 12:9, pages 1996-1999.
Crossref
Heinz Ludwig & Niklas Zojer. (2010) Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nature Reviews Clinical Oncology 7:5, pages 289-294.
Crossref
Monica De Matteo, Anna Elisabetta Brunetti, Eugenio Maiorano, Paola Cafforio, Franco Dammacco & Franco Silvestris. (2010) Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. Leukemia Research 34:2, pages 243-249.
Crossref
Meletios A. Dimopoulos & Evangelos Terpos. (2009) First-line bortezomib benefits patients with multiple myeloma. Nature Reviews Clinical Oncology 6:12, pages 683-685.
Crossref
Toyoko HiroiClayton B. DemingHaige ZhaoBaranda S. HansenElisabeth K. ArkenboutThomas J. MyersMichael A. McDevittJeffrey J. Rade. (2009) Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Krüppel-Like Transcription Factors. Arteriosclerosis, Thrombosis, and Vascular Biology 29:10, pages 1587-1593.
Crossref
Evangelos Terpos. (2008) Bortezomib directly inhibits osteoclast function in multiple myeloma: Implications into the management of myeloma bone disease. Leukemia Research 32:11, pages 1646-1647.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.